CNS Pharmaceuticals, Inc.
CNSP
$6.66
$0.152.30%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -13.07M | -15.46M | -15.61M | -14.86M | -17.06M |
| Total Depreciation and Amortization | 3.90K | 4.00K | 3.70K | 3.40K | 3.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 232.60K | 1.08M | 1.29M | 1.44M | 1.54M |
| Change in Net Operating Assets | -3.40M | -6.48M | -2.85M | -3.69M | 1.34M |
| Cash from Operations | -16.23M | -20.86M | -17.16M | -17.11M | -14.18M |
| Capital Expenditure | -4.20K | -4.20K | -4.20K | -4.20K | -2.20K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -4.20K | -4.20K | -4.20K | -4.20K | -2.20K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -298.00K | -299.10K | -300.10K | -300.90K | -340.40K |
| Issuance of Common Stock | 18.55M | 30.97M | 28.88M | 23.40M | 20.84M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 870.50K | 832.00K | 815.20K | -66.80K | -259.70K |
| Cash from Financing | 19.13M | 31.50M | 29.40M | 23.03M | 20.24M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.89M | 10.64M | 12.23M | 5.91M | 6.06M |